Report Summarizes Immunotherapy Study Findings from Jiangsu University (An Oncogene Regulating Chromatin Favors Response To Immunotherapy).

A recent study conducted at Jiangsu University in Zhenjiang, People's Republic of China, explored the role of chromatin regulators in influencing the efficacy of immune checkpoint inhibitors (ICIs) in gastric cancer (GC). The study identified CHAF1A as a key gene regulating chromatin that was associated with a favorable response to immunotherapy, independent of classic biomarkers. The research suggests that CHAF1A could serve as a novel biomarker for improving patient selection in immunotherapy. For more information, the study "An Oncogene Regulating Chromatin Favors Response To Immunotherapy" can be accessed through Oncoimmunology. [Extracted from the article]